KALA BIO (NASDAQ:KALA) Price Target Raised to $35.00

Key Points

• HC Wainwright has raised its price target for KALA BIO stock from $12.00 to $35.00, indicating a potential upside of 91.05% from its previous close.
• The stock has seen significant appreciation recently, trading at an opening price of $18.32 and having increased by 400% over the past month.
• Currently, KALA BIO holds a consensus rating of "Buy" from analysts, with an average price target of $27.50.

KALA BIO (NASDAQ:KALA - Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $12.00 to $35.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 78.30% from the stock's previous close. HC Wainwright also issued estimates for KALA BIO's Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($5.65) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.60) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.39) EPS and FY2026 earnings at ($5.89) EPS.

Other analysts have also recently issued reports about the stock. Mizuho initiated coverage on shares of KALA BIO in a research note on Monday, September 8th. They set an "outperform" rating and a $30.00 price target on the stock. Lifesci Capital raised shares of KALA BIO to a "strong-buy" rating in a report on Wednesday, September 3rd. Wall Street Zen cut shares of KALA BIO from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. LADENBURG THALM/SH SH began coverage on shares of KALA BIO in a report on Friday, July 11th. They issued a "buy" rating and a $12.00 price target on the stock. Finally, Oppenheimer upped their price target on shares of KALA BIO from $15.00 to $33.00 and gave the stock an "outperform" rating in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $27.50.

KALA BIO Stock Performance

Shares of KALA stock traded up $2.10 during trading on Wednesday, reaching $19.63. 369,708 shares of the company's stock traded hands, compared to its average volume of 294,266. The company has a market capitalization of $137.80 million, a P/E ratio of -2.89 and a beta of -1.81. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19. The firm's 50-day moving average is $10.12 and its 200 day moving average is $6.52. KALA BIO has a 1 year low of $2.92 and a 1 year high of $20.60.

KALA BIO (NASDAQ:KALA - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating analysts' consensus estimates of ($1.82) by $0.11. Equities research analysts expect that KALA BIO will post -10.84 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mark T. Iwicki sold 13,227 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total value of $53,040.27. Following the transaction, the director owned 258,433 shares in the company, valued at approximately $1,036,316.33. This represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 30,678 shares of company stock valued at $123,019 in the last 90 days. 8.32% of the stock is currently owned by corporate insiders.

Institutional Trading of KALA BIO

Several institutional investors have recently made changes to their positions in KALA. ADAR1 Capital Management LLC grew its stake in shares of KALA BIO by 35.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock worth $1,713,000 after buying an additional 78,582 shares in the last quarter. Readystate Asset Management LP bought a new position in KALA BIO during the 1st quarter valued at about $243,000. AIGH Capital Management LLC grew its holdings in KALA BIO by 61.9% during the 1st quarter. AIGH Capital Management LLC now owns 196,350 shares of the company's stock valued at $1,125,000 after purchasing an additional 75,048 shares during the last quarter. Woodline Partners LP bought a new position in KALA BIO during the 1st quarter valued at about $1,483,000. Finally, Geode Capital Management LLC grew its holdings in KALA BIO by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after purchasing an additional 1,534 shares during the last quarter. Hedge funds and other institutional investors own 24.61% of the company's stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.